In our study, in which we analyzed the efficacy of galectin-3 in predicting exacerbations and disease severity in COPD patients, we observed that galectin-3 levels were significantly higher in AECOPD patients than in stable COPD patients. This evidence concerns the gene LGALS3 and chronic obstructive pulmonary disease.